Jaguar Health, Inc.

NasdaqCM:JAGX 株式レポート

時価総額：US$9.6m

Jaguar Health マネジメント

マネジメント 基準チェック /44

Jaguar Healthの CEO はLisa Conteで、 Jun2013年に任命され、 の在任期間は 11.42年です。 の年間総報酬は$ 815.85Kで、 70.6%給与と29.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.18%を直接所有しており、その価値は$ 17.29K 。経営陣と取締役会の平均在任期間はそれぞれ3.9年と6.7年です。

主要情報

Lisa Conte

最高経営責任者

US$815.9k

報酬総額

CEO給与比率70.6%
CEO在任期間11.4yrs
CEOの所有権0.2%
経営陣の平均在職期間3.9yrs
取締役会の平均在任期間6.7yrs

経営陣の近況

Recent updates

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Jan 22
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jun 10
Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jan 23
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment

Oct 17

Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront

Aug 25

Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule

Aug 19

Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea

Aug 09

Jaguar stock rises on license deal with SynWorld for Canalevia in China

Jun 29

Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory

Mar 07

Jaguar Health shares jumps 13% after pricing $15M direct offering

Jan 13

Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients

Jan 11

Jaguar Health leaps higher in new year

Jan 05

Jaguar Health inks second Mytesi royalties agreement for $6M

Dec 23

Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Dec 02
Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%

Nov 30

Jaguar Health EPS misses by $0.10, misses on revenue

Nov 16

Jaguar Health receives positive Nasdaq listing determination

Oct 29

CEO報酬分析

Jaguar Health の収益と比較して、Lisa Conte の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$38m

Jun 30 2024n/an/a

-US$36m

Mar 31 2024n/an/a

-US$38m

Dec 31 2023US$816kUS$576k

-US$41m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$44m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$1mUS$603k

-US$47m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$3mUS$527k

-US$53m

Sep 30 2021n/an/a

-US$50m

Jun 30 2021n/an/a

-US$46m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020US$1mUS$500k

-US$39m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$39m

Mar 31 2020n/an/a

-US$45m

Dec 31 2019US$1mUS$500k

-US$45m

Sep 30 2019n/an/a

-US$48m

Jun 30 2019n/an/a

-US$43m

Mar 31 2019n/an/a

-US$34m

Dec 31 2018US$1mUS$480k

-US$32m

Sep 30 2018n/an/a

-US$41m

Jun 30 2018n/an/a

-US$30m

Mar 31 2018n/an/a

-US$24m

Dec 31 2017US$643kUS$440k

-US$22m

報酬と市場: Lisaの 総報酬 ($USD 815.85K ) は、 US市場 ($USD 647.72K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Lisaの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Lisa Conte (65 yo)

11.4yrs

在職期間

US$815,854

報酬

Ms. Lisa A. Conte serves as a Scientific Advisor at Triton Funds LLC. She is a Former Member of Scientific Advisory Board at Triton Funds LLC. She founded Jaguar Health, Inc. (formerly known as Jaguar Anim...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Lisa Conte
Founder11.4yrsUS$815.85k0.18%
$ 17.3k
Pravin Chaturvedi
Chief Scientific Officer & Chair of Scientific Advisory Board2.7yrsUS$627.13k0.054%
$ 5.2k
Jonathan Wolin
Chief of Staff6yrsUS$562.79k0.054%
$ 5.2k
Steven King
Chief of Sustainable Supply10.2yrsUS$491.54k0.054%
$ 5.1k
Carol Lizak
Chief Financial Officer4.7yrsデータなし0.046%
$ 4.5k
Peter Hodge
Senior Director of Investor Relationsno dataデータなしデータなし
Karen Brunke
Executive VP of Corporate & Business Development3.2yrsデータなしデータなし
David Sesin
Chief Manufacturing Officerno dataデータなしデータなし
Ian Wendt
Chief Commercial Officer3.9yrsUS$557.90kデータなし
Massimo Radaelli
President of Jaguar Internationalless than a yearデータなしデータなし
Catherine Collis
Senior Vice President of Growth Strategyless than a yearデータなしデータなし
Darlene Horton
Chief Medical Officerno dataデータなしデータなし

3.9yrs

平均在職期間

62yo

平均年齢

経験豊富な経営陣: JAGXの経営陣は 経験豊富 であると考えられます ( 3.9年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Lisa Conte
Founder11.4yrsUS$815.85k0.18%
$ 17.3k
Pravin Chaturvedi
Chief Scientific Officer & Chair of Scientific Advisory Board7.5yrsUS$627.13k0.054%
$ 5.2k
James Bochnowski
Independent Chairman10.8yrsUS$140.98k0.00041%
$ 39.4
John Micek
Independent Director8.6yrsUS$101.68k0.00024%
$ 23.1
Anula Jayasuriya
Independent Director2.3yrsUS$77.61k0.00031%
$ 29.8
Jonathan Siegel
Independent Director6.7yrsUS$104.18k0.00026%
$ 25.0
Sandra Swain
Member of Scientific Advisory Board1.8yrsデータなしデータなし
Kelly Shanahan
Scientific Advisory Board1.7yrsデータなしデータなし
Stacey Tinianov
Member of Scientific Advisory Board1.5yrsデータなしデータなし

6.7yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: JAGXの 取締役会 は 経験豊富 であると考えられます ( 6.7年の平均在任期間)。